Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Exon 14 Skipping”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04647838
What this trial is testing

Tepotinib in Solid Tumors Harboring MET Alterations

Who this might be right for
Solid TumorMET Exon 14 Skipping MutationMET Amplification
Chungbuk National University Hospital 100
Not applicableNo Longer AvailableNCT04741789
What this trial is testing

Managed Access Programs for INC280, Capmatinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04323436
What this trial is testing

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 31
Not applicableStudy completedNCT04575025
What this trial is testing

Special Drug Use-results Surveillance of Tabrecta Tablets

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 109
Testing effectiveness (Phase 2)Study completedNCT02750215
What this trial is testing

Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Who this might be right for
Malignant Non-small Cell Neoplasm of Lung Stage IV
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06031688
What this trial is testing

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
SWOG Cancer Research Network 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT02864992
What this trial is testing

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Who this might be right for
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV
EMD Serono Research & Development Institute, Inc. 337
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)WithdrawnNCT04992858
What this trial is testing

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Who this might be right for
Advanced NSCLC
Sunshine Lake Pharma Co., Ltd.
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40